Fesoterodine Fumarate Tablet, Film Coated, Extended Release
Product Images NDC 68382-479

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 68382-479). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cbef86b1 8a69 484d 87e8 05b6ecb06093 01

Chemical structure diagram of fesoterodine fumarate, the active ingredient. The structure includes distinct molecular groups and a fumaric acid moiety shown separately to indicate the salt form.*

FDA Label Image

Cbef86b1 8a69 484d 87e8 05b6ecb06093 02

A line graph depicting mean change from baseline in the number of micturitions per 24 hours over 12 weeks for placebo and fesoterodine fumarate 4 mg and 8 mg groups. The x-axis represents weeks (0 to 12), and the y-axis shows the mean change from baseline, with values decreasing over time, indicating changes in micturition frequency among the three groups.*

FDA Label Image

Cbef86b1 8a69 484d 87e8 05b6ecb06093 03

A line graph depicting mean change from baseline in urge incontinence episodes per 24 hours over 12 weeks for placebo, fesoterodine fumarate 4 mg, and fesoterodine fumarate 8 mg groups. The x-axis represents weeks (0 to 12) and the y-axis shows mean change. Three lines illustrate trends for placebo, 4 mg, and 8 mg doses.*

FDA Label Image

Cbef86b1 8a69 484d 87e8 05b6ecb06093 04

A line graph depicting the mean change from baseline in the number of micturitions per 24 hours over a 12-week period. The graph compares three groups: Placebo (dotted line with circles), Fesoterodine fumarate 4 mg (dashed line with triangles), and Fesoterodine fumarate 8 mg (solid line with squares). The x-axis shows weeks (0, 2, 8, 12) and the y-axis shows mean change from baseline values.*

FDA Label Image

Cbef86b1 8a69 484d 87e8 05b6ecb06093 05

A line graph comparing the mean change from baseline in urge incontinence episodes per 24 hours over a 12-week period. It shows three groups: placebo, fesoterodine fumarate 4 mg, and fesoterodine fumarate 8 mg, with the 8 mg dose showing the greatest decrease in episodes over time.*

FDA Label Image

Cbef86b1 8a69 484d 87e8 05b6ecb06093 06

Label for fesoterodine fumarate extended-release tablets, 4 mg strength. The label shows a bottle containing 90 film-coated tablets for oral use. Manufactured by Cadila Healthcare Ltd, Ahmedabad, India and distributed by Zydus Pharmaceuticals USA Inc. Includes storage instructions and states Rx only.*

FDA Label Image

Cbef86b1 8a69 484d 87e8 05b6ecb06093 07

Label for fesoterodine fumarate extended-release tablets, 8 mg strength, film-coated, oral tablets. The package contains 90 tablets. Label indicates the product is Rx only and manufactured by Cadila Healthcare Ltd., distributed by Zydus Pharmaceuticals USA Inc., Pennington, NJ. Includes storage instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.